Bevacizumab, a recombinant human monoclonal antibody, exerts an effect of antiangiogenesis by binding VEGF to block its biological function.7 ECOG4599 study randomly distributes 878 patients who suffer recurring or advanced NSCLC (stage IIIB or IV) in 2 groups, paclitaxel + carboplatin group and chemotherapy + bevacizumab group. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.